TD Cowen raised the firm’s price target on Danaher (DHR) to $270 from $260 and keeps a Buy rating on the shares. The firm adjusted targets in the life science tools space as part of a Q4 outlook. While the bar is higher for the Q4 results following the recent share rallies, many companies “already soft guided” 2026, the analyst tells investors in a research note. TD believes this sets room for upside in 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Danaher price target raised to $250 from $245 at Evercore ISI
- Danaher price target raised to $275 from $250 at Guggenheim
- The Week That Was, The Week Ahead: Macro & Markets, Dec. 20
- Marathon Petroleum CFO John Quaid to depart, Maria Khoury to succeed
- Danaher price target raised to $265 from $250 at BofA